Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01105533 · ClinicalTrials.gov registry record · Phase 1
A Dose Finding Study Of A New Medication, PF-00337210 That Will Possibly Decrease Blood Supply To Tumors
A Phase 1 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 46
- Enrollment target
NCT01105533 is a Phase 1 study that has completed, run by Pfizer. The registered enrollment target is 46 participants.
The verdict
NCT01105533, a Phase 1 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 46 participants
- Enrollment target
Study Summary
This study will test a new cancer medication to determine if this medication will block blood supply to a tumor and decrease growth of a tumor. This study will also define the safety profile and define the safest dose of this new medication for people who have cancer.
Interventions
- DRUG PF-00337210
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 46 participants |
| Start Date | 2006-05 |
| Est. Completion | 2011-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01105533
The ClinicalTrials.gov registry entry for NCT01105533 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 46 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which PF-00337210 is the first listed.
NCT01105533 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01105533 about?
NCT01105533 is a clinical study titled "A Dose Finding Study Of A New Medication, PF-00337210 That Will Possibly Decrease Blood Supply To Tumors". This study will test a new cancer medication to determine if this medication will block blood supply to a tumor and decrease growth of a tumor. This study will also define the safety profile and define the safest dose of this new medication for people who have cancer.
What is the current status of trial NCT01105533?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 46 participants. The study started on 2006-05. Estimated completion is 2011-09.
What interventions are being tested in trial NCT01105533?
The interventions under investigation include: PF-00337210 (DRUG).
Who is sponsoring clinical trial NCT01105533?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.